BGB-21447
- Generic Name
- BGB-21447
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Phase 1
Recruiting
- Conditions
- Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT06756932
- Locations
- ๐บ๐ธ
Hoag Memorial Presbyterian, Newport Beach, California, United States
๐บ๐ธUniversity of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
๐บ๐ธMd Anderson Cancer Center, Houston, Texas, United States
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Phase 1
Recruiting
- Conditions
- Refractory Chronic Lymphocytic LeukemiaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRelapsed Chronic Lymphocytic LeukemiaRelapsed Follicular LymphomaRelapsed Marginal Zone LymphomaRelapse Diffuse Large B Cell LymphomaRelapsed Small Lymphocytic LymphomaRefractory Follicular LymphomaRefractory Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 112
- Registration Number
- NCT05828589
- Locations
- ๐ฆ๐บ
Pindara Private Hospital, Benowa, Queensland, Australia
๐บ๐ธMission Cancer and Blood, Waukee, Iowa, United States
๐บ๐ธSidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath